Which of the following medications are commonly prescribed for patients suffering from obsessive-compulsive disorder (OCD)?

Choice A reason: Methylphenidate, a stimulant, targets dopamine and norepinephrine reuptake, primarily used for ADHD. OCD involves serotonin dysregulation in the cortico-striato-thalamo-cortical circuit. Stimulants may exacerbate anxiety by increasing catecholamine activity in the amygdala, worsening OCD symptoms, and are not indicated for OCD treatment due to lack of serotonin modulation. Choice B reason: Aripiprazole, an atypical antipsychotic, modulates dopamine D2 and serotonin 5-HT2 receptors. It’s used as an adjunct in treatment-resistant OCD but not first-line. OCD primarily involves serotonin deficits in the orbitofrontal cortex; aripiprazole’s primary action on dopamine doesn’t address this core pathology, limiting its efficacy as a standalone treatment. Choice C reason: Gabapentin, an anticonvulsant, enhances GABA activity, used for neuropathic pain and seizures. OCD’s pathophysiology centers on serotonin imbalance in the basal ganglia and prefrontal cortex. Gabapentin lacks direct effects on serotonin pathways, making it ineffective for OCD. It may reduce anxiety but doesn’t target compulsive behaviors driven by serotonergic dysfunction. Choice D reason: SSRIs, like sertraline, increase serotonin availability in synapses, targeting the cortico-striato-thalamo-cortical circuit’s dysregulation in OCD. Enhanced serotonin signaling in the orbitofrontal cortex and basal ganglia reduces obsessive thoughts and compulsions. SSRIs are first-line treatments due to their efficacy in modulating serotonin, supported by extensive clinical trials showing symptom reduction.